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Occupational immunological lung disease, due to low molecular weight, reactive chemicals such as trimellitic
anhydride (TMA), is an emerging health problem. If there were a marker that was highly predictive of the ability of
the immune system to recognize TMA as an allergen, better prevention strategies could be employed with at risk
individuals. The purpose of this study is to evaluate whether human leucocyte antigen (HLA) class specificity is
associated with the development of late respiratory systemic syndrome (LRSS) or asthma due to immunological
sensitivity to trimellitic anhydride (TMA). This is a case control study of 17 individuals with LRSS, 12 with asthma
and 22 TMA similarly exposed individuals who did not develop LRSS or asthma. Comparing the sensitized
individuals (LRSS or asthma) with the non-sensitized individuals (controls), we found no difference in frequency of
any HLA antigen. In summary, the lack of association of HLA antigens with LRSS or asthma due to TMA
suggests that these will not be useful markers to identify at risk individuals.
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Occupational immunological lung disease, due to low
molecular weight, reactive chemicals such as trimellitic
anhydride (TMA), is an emerging health problem (1). TMA
is one of several acid anhydrides used as a catalyst in the
manufacture of epoxy resins. In spite of low exposure
levels, approximately 10% of exposed individuals develop
asthma due to TMA. TMA can form covalent bonds with
proteins in the airway. TMA conjugated to human proteins
such as human serum albumin (HSA) can act as an
allergen. The presence of IgE against TMA conjugated to
HSA (TM-HSA) is highly associated with asthma due to
TMA while IgG against TM-HSA is associated with late
respiratory systemic syndrome (LRSS) (2).
At present, early detection of employees with immuno-
logical lung disease due to TMA is accomplished through
annual surveillance studies of exposed employees. In the
current climate of increasing healthcare cost, prevention
would, of course, be preferable to surveillance for disease. IfReceived 19 August 1999 and accepted in revised form 14 April
2000.
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of the immune system to recognize TM-HSA as an allergen,
better prevention strategies could be employed with
susceptible individuals. Obviously, a potential applicant
could not be denied a job because he or she was at high risk
for sensitization. However, the applicant could be coun-
seled that the likelihood of sensitization was high; the
applicant might decide not to take a job in which there was
a high likelihood of sensitization. The goal would be the
prevention of TMA immunological lung disease rather than
the current strategy of diagnosing the disease and moving
the individual to a job that involves less TMA exposure.
It has been reported in several studies of the human
immune response to ragweed allergens, Amb a V, Amb pV
and Amb t V, that MHC Class II specificities, HLA-DR2
and HLA-Dw2, are highly associated with the ability to
produce IgE against these antigens (3). A low molecular
weight chemical causing occupational asthma, toluene
diisocyanate (TDI), has been studied by Dr Fabbri and
co-workers in Italy. They have reported a significant
association between development of TDI asthma and a
certain MHC Class II specificity, HLA-DQB1*0503 (4). Dr
Baur’s group, however, has been unable to confirm the
importance of HLA Class II alleles in isocyanate induced
asthma (5).
Two groups of investigators have published studies
regarding the association of HLA allele frequency and
specific IgE against the corresponding acid anhydride-HSA# 2000 HARCOURT PUBLISHERS LTD
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between specific IgE against acid anhydride-HSA and the
MHC Class II specificity, HLA-DR3. This association was
particularly strong for TMA. A Swedish study of workers
exposed to two other anhydrides, hexahydrophthlic anhy-
dride (HHPA) and methyltetrahydrophthalic anhydride
(MTHPA), reported no association between MHC class
specificity and specific antibody in serum (7).
This study is a case control study to evaluate whether
HLA MHC class specificity is associated with the develop-
ment of LRSS or TMA asthma. The question of whether
susceptibility to asthma due to low molecular weight
sensitizers is predictable is an important question which
affects the health of hundreds of thousands of exposed
workers worldwide, and studies such as the present one will
be the only means to answer this question.
Methods
POTENTIAL STUDY POPULATION
The study population from which we could recruit subjects
consists of approximately 80 similarly exposed employees
who have been participating in our annual surveillance
studies at the manufacturing plant. Approximately 30
employees have developed an immunologically mediated
respiratory disease to TMA. About half of those developed
IgE against TM-HSA and TMA asthma, and the others
have developed LRSS and IgG against TM-HSA.
EXPOSURE CLASSIFICATION
An industrial hygienist at the manufacturing plant has
assigned an exposure classification to employees based on a
detailed knowledge of each job and on data obtained from
TMA personal monitoring of some employees in each
exposure classification (8). Exposure categories are 1 to 5,
with 1 being the highest exposure and 5 the lowest.
IMMUNOLOGICAL EVALUATION
Blood is drawn annually from each employee to assess IgE
and IgG antibody against TM-HSA in serum. These
serological tests were performed by radioimmunoassay
using standard methodology (9).
CLINICAL EVALUATION
A questionnaire developed jointly by the University of
Cincinnati and the National Institute for Occupational
Safety and Health to assess occupational immunological
lung disease was administered to each employee (10). Any
employee with positive symptoms on questionnaire and/or
positive antibody results was interviewed, examined and
skin tested with TM-HSA by a physician.
The criteria for IgE mediated TMA asthma have been
previously published (11). They are: compatible symptoms
including one or more of the following—cough, dyspnea,wheeze, chest tightness; physical findings of wheeze or
prolonged expiratory phase; obstructive PFTs post-expo-
sure; normal chest film; IgE antibody against TM-HSA
demonstrable by in vitro or in vivo assay. The criteria for
LRSS are: compatible symptoms including one or more of
the following: cough, fever, dyspnea; physical findings of
rales, tachypnea and fever; restrictive PFTs post-exposure;
basilar chest infiltrates; IgG antibody against TM-HSA.
CASE SUBJECTS
Case subjects were recruited from those employees who met
the criteria for TMA asthma or LRSS as defined above.
Informed consent was obtained. There were cases with
asthma and/or cases with LRSS.
CONTROL SUBJECTS
Control subjects were recruited from the employees who
had not developed IgE or IgG against TM-HSA. Controls
had no work related symptoms. Control subjects were
matched with case subjects for age, gender, race, smoking,
exposure category, and exposure duration.
REFERENT POPULATION
A reference population (Chicago control subjects) of 500
apparently healthy subjects, who had donated blood was
included for comparison on the prevalence of the HLA
Class I and II antigens.
HLA MHC CLASS TYPING
HLA MHC class typing was performed by the Tissue
Typing Laboratory at Northwestern using standard meth-
odology (12).
STATISTICAL ANALYSIS
Comparisons between groups for both categorical and
ordered attributes were conducted using the non-para-
metric statistical procedure, optimal discriminant analysis
(ODA) (13–15). When an attribute is dichotomous, the P-
value obtained via ODA is the same as would be obtained
had Fisher’s exact test been conducted. Because of the small
sample size of the LRSS and asthma groups, alpha
correction via the Bonferroni procedure was not performed:
effects were deemed statistically significant if the general-
ized (‘per-comparison’) Type I error was P50?05.
Results
DEMOGRAPHIC INFORMATION
The cases and controls were not significantly different in
terms of any demographic variable studied (Tables 1 and 2).
TABLE 1. Patient attribute comparison: control vs. LRSS patients
(Negative for LRSS) (Positive for LRSS)
Attribute Levels Control LRSS P-value
Cigarette Smoker Never n=10 n=2 0?33
Ex-smoker n=6 n=3
Current n=1 n=1
Other n=12 n=10
Packs per day Mean+SD 0?6+0?8 1?5+1?8 0?36
n=17 n=6
Years smoking Mean+SD 9?4+12?7 14?5+13?0 0?38
n=17 n=6
Age (years) Mean+SD 37?7+8?0 36?4+7?9 0?40
n=31 n=16
Sex Male n=31 n=14 0?71
Female n=0 n=2
Race Caucasian n=24 n=14 0?71
Non-caucasian n=6 n=2
Exposure Mean+SD 2?0+0?8 2?0+0?7 0?75
n=31 n=16
Note: Sample sizes vary due to missing data
TABLE 2. Patient attribute comparison: control vs. asthma patients
Attribute Levels Negative for asthma Positive for asthma P-value
Cigarette smoker Never n=10 n=2 0.78
Ex-smoker n=6 n=3
Current n=1 n=1
Other n=16 n=6
Packs per day Mean+SD 0?9+1?3 0?7+0?7 0?65
n=18 n=5
Years smoking Mean+SD 10?8+13?6 10?6+9?9 0?81
n=18 n=5
Age (years) Mean+SD 39?0+7?3 32?2+7?7 0?06
n=35 n=12
Sex Male n=34 n=12 0?99
Female n=1 n=1
Race Caucasian n=29 n=9 0?99
Non-caucasian n=6 n=2
Exposure Mean+SD 2?1+0?8 1?7+0?7 0?09
n=35 n=12
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Only one statistical comparison was statistically significant
(Tables 3, 4 and 5). A greater proportion of the TM control
patients were positive for the B7 antigen than were the
Chicago control patients (38% vs. 18%, respectively,
P50?029). Since a total of 123 tests of statistical hypothesis
were conducted and then evaluated for statistical signifi-
cance under the generalized (‘per-comparison’) criterion of
P50?05, a total of 0?056123, or six ‘statistically signifi-cant’ effects would be expected by chance alone. Thus, the
finding of only one significant effect reflects less than 17%
of the number of significant effects that would be expected
by chance alone.
Discussion
Occupational immunological lung disease due to low
molecular weight chemicals like TMA is an emerging
TABLE 3. Antigen comparison, control vs. LRSS patients
Controls (n=22) LRSS (n=17)
Antigen n Positive n Negative n Positive n Negative P
A1 4 18 5 12 0?47
A2 12 10 11 6 0?75
A3 4 18 5 12 0?47
A9 3 19 4 13 0?68
A10 2 20 0 17 0?50
A11 5 17 1 16 0?21
A28 2 20 2 15 0?99
A29 2 20 0 17 0?50
AW30 3 19 2 15 0?99
AW31 1 21 1 16 0?99
AW32 2 20 3 14 0?64
Blank 4 18 0 17 0?12
B5 1 21 0 17 0?99
B7 9 13 6 11 0?76
B8 3 19 3 14 0?99
B12 4 18 4 13 0?71
B13 1 21 2 15 0?58
B14 3 19 1 16 0?62
B15 1 21 3 14 0?30
B16 1 21 2 15 0?58
B17 2 20 3 14 0?64
B18 2 20 0 17 0?50
B27 3 19 2 15 0?99
BW35 4 18 3 14 0?99
B40 2 20 4 13 0?38
B21 2 20 0 17 0?50
Blank 6 16 1 16 0?12
DR1 5 17 2 15 0?44
DR3 5 17 2 15 0?44
DR4 8 14 7 10 0?99
DR5 4 18 4 13 0?71
DRW6 6 16 2 15 0?43
DR7 5 17 6 11 0?49
DRW8 0 22 3 14 0?08
Blank 6 16 1 16 0?12
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missed workdays and healthcare costs (16). The current
approach is that of periodic surveillance and diagnosing
TMA asthma after the individual has already developed
disease. If asthma or LRSS are diagnosed at an early stage
after the individual has been symptomatic for only a few
months, there are no permanent sequelae. Therefore,
vigilant surveillance studies do provide appropriate protec-
tion of exposed individuals from permanent lung damage.
However, a preferable approach would be that of
identifying a marker that is predictive of which individuals
are genetically susceptible to recognize TM-protein as an
allergen, to develop IgE or IgG against TM-protein and
ultimately, TMA induced immunological lung disease.
Individuals could be counseled about their high risk ofsensitization which could affect their behavior in a variety
of positive ways. For instance, if they decided to take the
job, they might be more attentive to early signs and
symptoms of occupational immunological lung disease. A
good candidate for such a predictive marker is human
leucocyte antigen (HLA) major histocompatibility complex
(MHC) Class II specificity. This is because immune
responsiveness of a given individual to a given allergen is
highly dependent upon the ability of that allergen to bind to
HLA Class II molecules on the surface of that individual’s
T lymphocytes. If an individual’s HLA Class II molecules
cannot bind the allergen, it cannot be recognized by that
individual’s immune system. Conversely, an individual’s
immune system can recognize an allergen that will bind to
its HLA Class II molecules (17).
TABLE 4. Antigen compresions: control vs. asthma patients
Controls (n=22) Asthma (n=12)
Antigen n Positive n Negative n Positive n Negative P5
A1 4 18 5 7 0?23
A2 12 10 6 6 0?99
A3 4 18 3 9 0?68
A9 3 19 2 10 0?99
A10 2 20 1 11 0?99
A11 5 17 1 11 0?39
A28 2 20 0 12 0?53
A29 2 20 0 12 0?53
AW30 3 19 1 11 0?99
AW31 1 21 1 11 0?99
AW32 2 20 2 10 0?61
Blank 4 18 2 10 0?99
B5 1 21 1 11 0?99
B7 9 13 2 10 0?26
B8 3 19 3 9 0?65
B12 4 18 3 9 0?68
B13 1 21 2 10 0?28
B14 3 19 0 12 0?54
B15 1 21 1 11 0?99
B16 1 21 2 10 0?28
B17 2 20 2 10 0?61
B18 2 20 1 11 0?99
B27 3 19 2 10 0?99
BW35 4 18 3 9 0?68
B40 2 20 4 8 0?16
B21 2 20 0 12 0?53
Blank 6 16 2 10 0?69
DR1 5 17 2 10 0?99
DR2 5 17 5 7 0?28
DR3 5 17 2 10 0?99
DR4 8 14 5 7 0?99
DR5 4 18 3 9 0?68
DRW6 6 16 0 12 0?07
DR7 5 17 4 8 0?69
DRW8 0 22 2 10 0?12
Blank 6 16 2 10 0?69
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study to compare individuals with TMA asthma to
appropriately matched controls in terms of HLA MHC
class specificity. This study design has been used success-
fully by others (4–7). IgE responsiveness against other
allergens, Amb a V, Amb p V and Amb t V, has been found
to be highly associated with MHC Class II specificities (3).
Some investigators have found HLA associations with
asthma due to isocyanate and acid anhydrides while others
have not (4–7). We did not find an association in this study.
Other investigators have reported HLA-DR3 as an
association. There was no difference in our study of
HLA-DR3 in sensitized and non-sensitized individuals.We have followed these controls for more than a decade to
be certain that they would not develop OILD with
additional exposure. Our findings are similar to those of
Nielson and colleagues who also could find no HLA MHC
class association.
It should be noted that our small, imbalanced samples
yielded low statistical power (10–45%) for detecting
differences between groups. This could have been a problem
if, for instance, the individuals with TMA asthma had a
particular HLA allele at a three-fold higher frequency than
controls, but that difference was not statistically significant.
This would obviously raise the issue of the power of the
study. In our study, the sensitized individuals have
TABLE 5. Antigen compresions: TM control vs. Chicago control patients
TM Controls (n=24) Chicago Controls (n=500)
Antigen n Positive n Negative n Positive n Negative P
A1 4 20 125 375 0?47
A2 12 11 230 270 0?54
A3 4 20 120 380 0?63
A9 4 20 90 410 0?99
A10 2 22 75 425 0?56
A11 5 17 65 435 0?35
A28 3 21 50 450 0?73
A29 2 22 35 465 0?69
AW30 3 21 25 475 0?14
AW31 1 23 30 470 0?99
AW32 3 21 35 465 0?41
Blank 4 20
B5 1 23 55 445 0?50
B7 9 15 90 410 0?029
B8 3 21 100 400 0?60
B12 5 19 120 380 0?99
B13 1 23 25 475 0?99
B14 3 21 49 451 0?73
B15 1 23 49 451 0?72
B16 2 22 50 450 0?99
B17 2 22 55 445 0?99
B18 2 22 50 450 0?99
B27 3 21 35 465 0?41
BW35 4 20 80 420 0?99
B40 3 21 60 440 0?99
B21 2 22 35 465 0?69
Blank 6 18
DR1 5 19 99 401 0?80
DR2 5 19 126 374 0?82
DR3 6 18 115 385 0?81
DR4 8 16 150 350 0?83
DR5 4 20 95 405 0?99
DRW6 7 17 135 365 0?82
DR7 5 19 114 386 0?99
DRW8 2 22 48 452 0?99
DRW10 0 24 10 490 0?99
Blank 6 18 150 350 0?82
HLA AND TMA IMMUNOLOGICAL DISEASE 969essentially the same HLA allele frequency as the controls.
Therefore, we did not believe that power was an issue. In
order to verify this, we assessed whether statistically
significant effects would emerge if we had large samples.
To do this, we repeated the analyses after first multiplying
the sample size by 10, an order of magnitude. For this
hypothetical sample, there were more than three times the
number of statistically significant effects than would be
expected by chance alone. However, none of the statistically
significant effects was judged to be clinically significant as
defined by a relative risk 42.
In summary, we tested the hypothesis that the specificity
of IgE or IgG and associated asthma or LRSS wasassociated with HLA MHC allele frequency. The lack of
association suggests that these will not be useful markers to
identify at risk individuals. Further studies with anhydrides
and other agents will be important to future define the
utility of HLA alleles in susceptibility to occupational
immunological lung disease.
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